罢免案被否！688373，将迎“久违”实控人

Core Viewpoint - The control dispute over Mengke Pharmaceutical has been resolved with the approval of a capital increase plan, allowing Hai Jing Pharmaceutical to become the controlling shareholder, ending the company's three-year period without a controlling entity [1][2]. Group 1: Capital Increase Plan - On October 9, Mengke Pharmaceutical held its second extraordinary general meeting of shareholders in 2025, where the approximately 1.033 billion yuan capital increase plan was approved with a high voting rate [2][6]. - Key proposals, including the issuance plan and the introduction of strategic investors, received over 81% approval, with the proposal for issuing shares to specific targets achieving a 81.73% approval rate [2][4]. Group 2: Shareholder Dynamics - The proposal to dismiss the chairman and three directors put forth by the largest shareholder, Genie Pharma, was rejected, with nearly 80% voting against it [4][6]. - The meeting saw a high participation rate, with 438 shareholders and proxies representing 60.41% of the total shares [6]. Group 3: Company Financials and Future Prospects - Mengke Pharmaceutical has been in a state of loss, with cumulative losses exceeding 1.3 billion yuan from 2021 to 2024, although revenue increased by 10.26% in the first half of 2025 [7]. - The introduction of Hai Jing Pharmaceutical is expected to provide financial support and enhance the company's development capabilities, particularly in commercializing its core product, Kangti Zuoan tablets [12]. Group 4: Hai Jing Pharmaceutical Overview - Hai Jing Pharmaceutical is a research-driven modern pharmaceutical company, with steady revenue growth from 486 million yuan in 2022 to 648 million yuan in 2024, and a net profit of 104 million yuan in 2024 [8][9]. - The strategic partnership aims to leverage Hai Jing's established sales network and production capabilities to enhance Mengke's market penetration and production efficiency [12].